Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Long-Term Investments (2020 - 2023)

Historic Long-Term Investments for Gyre Therapeutics (GYRE) over the last 9 years, with Q4 2023 value amounting to $49.7 million.

  • Gyre Therapeutics' Long-Term Investments rose 2233.95% to $49.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was $49.7 million, marking a year-over-year increase of 2233.95%. This contributed to the annual value of $49.7 million for FY2023, which is 2233.95% up from last year.
  • Gyre Therapeutics' Long-Term Investments amounted to $49.7 million in Q4 2023, which was up 2233.95% from $40.6 million recorded in Q4 2022.
  • In the past 5 years, Gyre Therapeutics' Long-Term Investments registered a high of $49.7 million during Q4 2023, and its lowest value of $1.2 million during Q3 2020.
  • Its 3-year average for Long-Term Investments is $23.5 million, with a median of $21.6 million in 2020.
  • The largest annual percentage gain for Gyre Therapeutics' Long-Term Investments in the last 5 years was 2233.95% (2023), contrasted with its biggest fall of 2233.95% (2023).
  • Gyre Therapeutics' Long-Term Investments (Quarter) stood at $2.5 million in 2020, then soared by 1497.8% to $40.6 million in 2022, then rose by 22.34% to $49.7 million in 2023.
  • Its Long-Term Investments was $49.7 million in Q4 2023, compared to $40.6 million in Q4 2022 and $2.5 million in Q4 2020.